Celyad's novel CAR T-cell therapy for solid malignancies

Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4.

Abstract

Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic / methods
  • Drug Approval
  • Drug Industry
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Immunotherapy, Adoptive* / trends
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Receptors, Chimeric Antigen / genetics
  • Receptors, Chimeric Antigen / metabolism
  • Receptors, Chimeric Antigen / therapeutic use*
  • Research Design
  • T-Lymphocytes / physiology*
  • T-Lymphocytes / transplantation
  • Therapies, Investigational* / methods
  • Therapies, Investigational* / trends
  • United States
  • United States Food and Drug Administration

Substances

  • Receptors, Chimeric Antigen